Elotuzumab for previously treated multiple myeloma (terminated appraisal)
Technology appraisal
Reference number: TA434
Published:
This appraisal has been suspended because the manufacturer of elotuzumab has informed NICE it will not be able to make a submission for this appraisal.
Our normal procedure in these circumstances is to publish termination guidance.